Key result
Intralesional platelet-rich plasma achieves a good VASI response in ~38% of refractory vitiligo patients.
Answers are grounded in this paper and cite their sources.
Background: Vitiligo is a disease caused by destruction of melanocytes in lesional skin. It occurs worldwide in occurance of 0.1 to 2.0 percent. It is a multifactorial polygenic disease with complex pathogenesis. Several treatments, old and new are advocated for such patients. The first line of treatment includes topical corticosteroids and calcineurin inhibitors, and phototherapy (NBUVB, PUVA). The second line of treatment includes systemic corticosteroids, topical calcipotriol 0.005%, lasers such as excimer laser (308 nm). The aim of the study was to evaluate the efficacy of platelet rich plasma in 40 cases of stable vitiligo with less than or equal to 1% body surface area involvement. Methods: 40 cases of stable vitiligo not responding to adequate topical therapy for more than 1 year were included in the study. They were subjected to intralesional injections of freshly prepared autologous platelet rich plasma (PRP) by double spin technique. Each patient was given injections every 2 weekly interwals for a total of 6 injections. Results were evaluated using the vitiligo area severity index (VASI) score. Results: Out of 40 patients15 Patients showed good response, 12 patients showed Average response and13 patients showed no response to treatment according to VASI score. Conclusions: PRP may be considered as an additional therapy in patients not responding adequately to traditional therapies. Our patients were not subjected to histopathology. It was also felt that patients might require more than 6 sittings for complete repigmentation.
No takes yet. Share an insight, caveat, or question.
Mahajan et al. (2018) studied Chronic localized stable vitiligo (n=40). Intralesional autologous platelet rich plasma (PRP) was evaluated on Good response according to the Vitiligo Area Severity Index (VASI) score. Intralesional platelet-rich plasma produced a good VASI response in 37.5% (15/40) and average response in 30% (12/40) of patients with refractory stable vitiligo.
Synapse has enriched 10 related papers. Consider them for comparative context: